ATIR101

BIOLOGICAL2 trials

Sponsors

Kiadis Pharma

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome

Phase 2

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

CompletedNCT02500550

Kiadis PharmaAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2015-10-09End: 2018-12-17Updated: 2021-05-18

Phase 3

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

TerminatedNCT02999854

Kiadis PharmaAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2017-11-29End: 2021-12-17Updated: 2022-05-24

Related Papers

Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide

Blood2019-11-13

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Blood2019-11-13

PF767 PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ONE OR TWO DOSES OF DONOR LYMPHOCYTES DEPLETED OF HOST ALLOREACTIVE T‐CELLS (ATIR101) FOLLOWING T‐CELL‐DEPLETED HAPLOIDENTICAL HSCT

HemaSphere2019-06-01

A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies

Biology of Blood and Marrow Transplantation2019-01-311 citations

Differential Outcomes for Ex Vivo Versus In Vivo Alloreactive T-Cell Depletion Strategies in Haploidentical HSCT

Biology of Blood and Marrow Transplantation2019-01-31

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Blood2018-11-293 citations

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Blood2018-11-29